Frontage Laboratories has acquired Concord Biosciences, formerly known as Ricerca Biosciences, a preclinical contract research organization (CRO). 

Concord Bio supports the pharmaceutical, agricultural, chemical and animal health industries with drug safety, metabolism, bioanalytical, residue and environmental fate studies.

“We have committed to build a global CRO company with integrated services,” said Dr. Song Li, founder and chief executive officer, Frontage Laboratories. “The acquisition of Concord Biosciences is a significant step toward reaching our goal. The addition of Concord Bio to the Frontage family will enable us to provide pharmaceutical product development services from lead selection to IND-enabling studies to commercialization. Additionally, the agrochemical expertise of Concord Bio will position Frontage as a major CRO in the agricultural products industry.”